Sofosbuvir and ledipasvir improve patient‐reported outcomes in patients co‐infected with hepatitis C and human immunodeficiency virus
Authors:
- 13 June 2016
- journal article
- clinical trial
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 23 (11) , 857-865
Abstract
Summary: A fixed‐dose combination of ledipasvir and sofosbuvir (LDV/SOF) has been approved for treatment of HCV patients. We assessed the effect of LDV/SOF on patient‐reported outcomes (PROs) in HIV–HCV‐co‐infected patients. Patient‐reported outcomes data from HIV–HCV‐co‐infected patients who were treated with LDV/SOF for 12 weeks were collected as a part of a clinical trial (ION‐4). Historical controls were HIV–HCV‐co‐infected patients treated with SOF and ribavirin (RBV) in PHOTON‐1. We included 335 HIV–HCV‐co‐infected patients (SVR‐12 in HCV genotype 1 was 96%) who received LDV/SOF, while 223 patients (SVR‐12 in HCV genotype 1 was 76.3%) received SOF/RBV. During treatment, patients receiving LDV/SOF showed improvement in all of their PRO scores (+6.0% in activity/energy of CLDQ‐HCV, +5.0% in fatigue score of FACIT‐F, +6.8% in physical component of SF‐36; all P < 0.0001) while those receiving SOF+RBV showed moderate decline in some of their PRO scores (−4.8% in physical functioning of SF‐36, −4.4% in fatigue score of FACIT‐F, both P < 0.001). Patients who achieved sustained virologic response with LDV/SOF also showed improvement of PROs (average +5.1%) while those treated with SOF/RBV showed less or no improvement (average +1.4%). In a multivariate analysis, in addition to depression and fatigue, receiving SOF+RBV (vs LDV/SOF) was independently associated with more PRO impairment during treatment (beta −6.1 to −12.1%, P < 0.001). Hence, HIV–HCV patients treated with LDV/SOF show significant improvement of their health‐related quality of life and other patient‐reported outcomes during treatment and after treatment cessation.Keywords
Funding Information
- Gilead Sciences
This publication has 25 references indexed in Scilit:
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyThe Lancet, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCVNew England Journal of Medicine, 2014
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3New England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without CirrhosisNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsNew England Journal of Medicine, 2013
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis CNew England Journal of Medicine, 2013